Paper - WANFANG MED ONLINE

You Position: Home > Paper

Multimodality brain tumor imaging: MR imaging, PET, and PET/MR imaging

( views:251, downloads:291 )

Author:: No author available

Journal Title:: Chinese Journal of Nuclear Medicine and Molecular Imaging

Issue:: 11

DOI:: 10.2967/jnumed.113.131516

Key Word:: 磁共振成像;正电子发射断层显像术;脑肿瘤

Abstract：常规的MRI和CT常被用于脑肿瘤解剖成像.治疗前计划和疗效评估很大程度上依赖于MR对比剂钆的增强扫描.先进的MR和PET显像技术能提供肿瘤的生理代谢或生物学功能信息,因此其诊断优势超出常规MR解剖成像.随着PET/MR的出现,肿瘤的研究进入了新领域.联合PET和MR的多模态显像可同时研究肿瘤不同模态代谢信息间的关系.本综述主要通过回顾MR和PET显像技术在脑肿瘤患者中的应用,为脑肿瘤的解剖和生理代谢提供临床实践的相关概述,并为脑肿瘤的进一步研究打下基础.

Reference

[1]A, Panigrahy,M D, Krieger,I, Gonzalez-Gomez,etc.Quantitative short echo time 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization.[J].2006,27.
[2]Mori S,van Zijl PC.Fiber tracking: principles and strategies - a technical review.[J].2002,15(7/8).
[3]Spence AM,Muzi M,Mankoff DA,etc.True tracers: comparing FDG with glucose and FLT with thymidine.[J].2005,32(7).
[4]R J, Jackson,G N, Fuller,D, Abi-Said,etc.Limitations of stereotactic biopsy in the initial management of gliomas.[J].2001,3(3).
[5]Parsa AT,Dillon WP,Cha S,etc.Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury.[J].2005,103(3).
[6]Claussen CD,Pichler BJ,Bisdas S,etc.Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT.[J].2010,51(8).
[7]Lester Kwock,J. Keith Smith,Mauricio Castillo,etc.Clinical Applications of Proton MR Spectroscopy in Oncology[J].2002,1(1).
[8]Xin Li,Seymur Gahramanov,Leslie L. Muldoon,etc.Pseudoprogression of Glioblastoma after Chemo- and Radiation Therapy: Diagnosis by Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging with Ferumoxytol versus Gadoteridol and Correlation with Survival[J].2013,266(3).
[9]Jain,R.,Hwang,S.N.,Wintermark,M.,etc.Genomic mapping and survival prediction in glioblastoma: Molecular subclassification strengthened by hemodynamic imaging biomarkers[J].2013,267(1).
[10]Clark, C.A.,Bell, B.A.,Byrnes, T.J.D.,etc.Diffusion tensor imaging discriminates between glioblastoma and cerebral metastases in vivo[J].2011,24(1).
[11]Miller DC,Kelly PJ,Kricheff II,etc.Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging.[J].1999,211(3).
[12]Flentje M,Staab A,Vince GH,etc.Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.[J].2007,83(3).
[13]Michael H, Lev,Yelda, Ozsunar,John W, Henson,etc.Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].[J].2004,25.
[14]P J, Basser,C, Pierpaoli.Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI.[J].1996,111(3).
[15]Chenevert TL,Meyer CR,Junck L,etc.Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.[J].2011,17(14).
[16]M, Peck,H A, Pollack,A, Friesen,etc.Applications of PET imaging with the proliferation marker [18F]-FLT.[J].2015,59.
[17]Bhattacharyya A,Pal D,Husain.In vivo proton MR spectroscopy evaluation of pyogenic brain abscesses: a report of 194 cases.[J].2010,31(2).
[18]Asenbaum S,Knosp E,Czech T,etc.Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement.[J].2011,82(5).
[19]B. R. Rosen,J. W. Belliveau,H. J. Aronen,etc.Susceptibility contrast imaging of cerebral blood volume: Human experience[J].1991,22(2).
[20]Taal W,Brandsma D,Stalpers L,etc.Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.[J].2008,9(5).
[21]Lamborn KR,Mikkelsen T,Galanis E,etc.Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.[J].2010,28(11).
[22]van-Zijl PC,Beauchamp NJ Jr,Ulug AM,etc.MR diffusion imaging in stroke: review and controversies.[J].1998,18(5).
[23]Grierson JR,Kolb PD,Wiens LW,etc.Validation of FLT Uptake as a Measure of Thymidine Kinase-1 Activity in A549 Carcinoma Cells.[J].2002,43(9).
[24]Junck L,Hayman J,Lee IH,etc.Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.[J].2009,73(2).
[25]D, Le Bihan,E, Breton,D, Lallemand,etc.MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders.[J].1986,161.
[26]Bailey, D. L.,Antoch, G.,Bartenstein, P.,etc.Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tubingen, Germany[J].2015,17(3).
[27]Delbeke D,Meyerowitz C,Kessler RM,etc.Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET.[J].1995,195(1).
[28]A J, Kumar,N E, Leeds,G N, Fuller,etc.Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.[J].2000,217.
[29]P S, Tofts,G, Brix,D L, Buckley,etc.Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.[J].1999,10(3).
[30]Pauleit D,Bachofner A,Stoffels G.Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.[J].2009,36(7).
[31]A, Romano,G, D'Andrea,G, Minniti,etc.Pre-surgical planning and MR-tractography utility in brain tumour resection.[J].2009,19(12).
[32]Wei, Chen,Timothy, Cloughesy,Nirav, Kamdar,etc.Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.[J].2005,46.
[33]Alexander M, Spence,Mark, Muzi,Kristin R, Swanson,etc.Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.[J].2008,14.
[34]Pham P,Muzi M,Lewellen B,etc.18F-FDG PET of Gliomas at Delayed Intervals: Improved Distinction Between Tumor and Normal Gray Matter.[J].2004,45(10).
[35]Roland, Ullrich,Heiko, Backes,Hongfeng, Li,etc.Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.[J].2008,14.
[36]Lucas,Prat R,Galeano I.Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas.[J].2010,17(1).
[37]S J, Price,R, Jena,N G, Burnet,etc.Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study.[J].2006,27.
[38]van den Bent MJ,Chamberlain M,Chang SM,etc.Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.[J].2011,12(6).
[39]Schlemmer HP,Michel C,Jacob PK,etc.Simultaneous MR/PET imaging of the human brain: feasibility study.[J].2008,248(3).
[40]Schiepers C,Satyamurthy N,Cloughesy T,etc.18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.[J].2006,47(6).
[41]Chenevert TL,Ross DJ,Meyer CR,etc.The parametric response map is an imaging biomarker for early cancer treatment outcome.[J].2009,15(5).
[42]Padma MV,Said S,Jacobs M,etc.Prediction of pathology and survival by FDG PET in gliomas.[J].2003,64(3).
[43]Hamstra DA,Galban CJ,Meyer CR,etc.Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.[J].2008,26(20).
[44]White ML,Yu F,Jaffar Kazmi SA,etc.Diffusion tensor MR imaging of cerebral gliomas: evaluating fractional anisotropy characteristics.[J].2011,32(2).
[45]Brandsma,D.,VanDenBent,M.J..Pseudoprogression and pseudoresponse in the treatment of gliomas[J].2009,22(6).
[46]Hiroyuki Kobayashi,Nagara Tamaki,Shunsuke Terasaka,etc.1?F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.[J].2012,39(5).
[47]Maravilla,K.R.,Rockhill,J.K.,Haynor,D.R.,etc.Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects[J].2012,35(1).
[48]Ritz,R.,Braun,C.,Bender,B.,etc.Metabolic mapping of gliomas using hybrid MR-PET imaging: Feasibility of the method and spatial distribution of metabolic changes[J].2013,48(5).
[49]Shields AF,Grierson JR,Machulla HJ,etc.Imaging proliferation in vivo with (F-18)FLT and positron emission tomography.[J].1998,4(11).
[50]Levivier M,Goldman S,Pirotte BJ.Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients.[J].2009,64(3).
[51]Gupta A,Shi W,Graber JJ,etc.Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.[J].2011,76(22).
[52]Smits,M,Vernooij,MW,Wielopolski,PA,etc.Incorporating functional MR imaging into diffusion tensor tractography in the preoperative assessment of the corticospinal tract in patients with brain tumors.[J].2007,28(7).
[53]Schmainda KM,Paulson ES.Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.[J].2008,249(2).
[54]Gruber ML,Law M,Young RJ,etc.Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.[J].2008,247(2).
[55]Vaupel P,Hockel M.Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.[J].2001,93(4).
[56]Z, Grunbaum,S J, Freauff,K A, Krohn,etc.Synthesis and characterization of congeners of misonidazole for imaging hypoxia.[J].1987,28.
[57]Barton SJ,Wilkins P,Howe FA,etc.Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy.[J].2003,49(2).
[58]Scarpace L,Hearshen D,Mikkelsen T,etc.Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis.[J].2004,54(5).
[59]A I, Holodny,M, Schulder,W C, Liu,etc.The effect of brain tumors on BOLD functional MR imaging activation in the adjacent motor cortex: implications for image-guided neurosurgery.[J].2000,21.
[60]Muzi M,Spence AM,Link JM.NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-(18F)fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.[J].2009,11(5).
[61]Marras C,Danesi U,Bizzi A,etc.Presurgical functional MR imaging of language and motor functions: validation with intraoperative electrocortical mapping.[J].2008,248(2).
[62]Costanzo, A.,Scarabino, T.,Trojsi, F.,etc.Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach[J].2014,119(8).
[63]K, Kono,Y, Inoue,K, Nakayama,etc.The role of diffusion-weighted imaging in patients with brain tumors.[J].1900,22.
[64]H C, Roberts,T P, Roberts,A W, Bollen,etc.Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors.[J].2001,8(5).
[65]Dahabreh,I.J.,Terasawa,T.,Nihashi,T..Diagnostic accuracy of PET for recurrent glioma diagnosis: A meta-analysis[J].2013,34(5).
[66]Adrian L, Harris.Hypoxia--a key regulatory factor in tumour growth.[J].2002,2(1).
[67]John L, Ulmer,Carmen V, Salvan,Wade M, Mueller,etc.The role of diffusion tensor imaging in establishing the proximity of tumor borders to functional brain systems: implications for preoperative risk assessments and postoperative outcomes.[J].2004,3.
[68]Majos C,Aguilera C,Acebes JJ,etc.Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas.[J].2011,32(1).
[69]Bagadia A,Purandare H,Misra BK,etc.Application of magnetic resonance tractography in the perioperative planning of patients with eloquent region intra-axial brain lesions.[J].2011,18(5).
[70]Reith W,Sartor K,Debus J,etc.Simultaneous assessment of cerebral hemodynamics and contrast agent uptake in lesions with disrupted blood-brain-barrier.[J].1999,17(1).
[71]O'Sullivan F,Spence AM,Grierson JR,etc.Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.[J].2006,47(10).
[72]Wen PY,Sampson JH,Macdonald DR,etc.Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.[J].2012,70(1).
[73]P E, Valk,W P, Dillon.Radiation injury of the brain.[J].1991,12.
[74]Pillai JJ.The evolution of clinical functional imaging during the past 2 decades and its current impact on neurosurgical planning.[J].2010,31(2).